Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program

Antithrombotic prophylaxis with oral anticoagulation (OAC) substantially reduces stroke and mortality in patients with atrial fibrillation (AF).

[1]  J. Healey,et al.  Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation , 2018 .

[2]  Mircea Cinteza,et al.  A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial , 2017, The Lancet.

[3]  G. Lip,et al.  The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey , 2017, Advances in Therapy.

[4]  J. Healey,et al.  Stroke Prevention for Patients with Atrial Fibrillation: Beyond the Guidelines. , 2017, Journal of atrial fibrillation.

[5]  G. Lip,et al.  The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. , 2017, Journal of the American College of Cardiology.

[6]  G. Lip,et al.  International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives , 2016, Journal of the American Heart Association.

[7]  J. Healey,et al.  2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. , 2016, The Canadian journal of cardiology.

[8]  A. Camm,et al.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation , 2016, Heart.

[9]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[10]  M. Turakhia,et al.  Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. , 2016, Journal of the American College of Cardiology.

[11]  A. Baranchuk,et al.  Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. , 2016, The Canadian journal of cardiology.

[12]  M. Turakhia,et al.  Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. , 2016, JAMA cardiology.

[13]  G. Lip,et al.  Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. , 2015, The American journal of medicine.

[14]  Y. Chun,et al.  Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry , 2015, Stroke.

[15]  J. Olesen,et al.  Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study , 2015, BMJ : British Medical Journal.

[16]  G. Lip,et al.  Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study , 2015, Circulation.

[17]  G. Lip,et al.  Patterns in atrial fibrillation management and ‘real-world’ adherence to guidelines in the Balkan Region: an overview of the Balkan–atrial fibrillation survey. , 2015, European heart journal.

[18]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[19]  Á. Avezum,et al.  Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. , 2015, European heart journal.

[20]  G. Lip,et al.  Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  G. Lip,et al.  Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2014, The American journal of medicine.

[22]  B. Guthrie,et al.  Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: Cross-sectional population database study , 2014, The European journal of general practice.

[23]  G. Lip,et al.  Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. , 2014, American heart journal.

[24]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[25]  P. Kirchhof,et al.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF) , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  G. Lip,et al.  Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[27]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[28]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[29]  D. Singer,et al.  Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2013, Circulation.

[30]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[31]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[32]  J. Tolstrup,et al.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.

[33]  A. Capucci,et al.  Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring , 2011, Stroke.

[34]  C. Albert,et al.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.

[35]  L. Newby,et al.  Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. , 2011, American heart journal.

[36]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[37]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[38]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[39]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[40]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[41]  S. Connolly,et al.  Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. , 2006, American heart journal.

[42]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[43]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[44]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[45]  A. Laupacis,et al.  Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. , 1999, Archives of internal medicine.

[46]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[47]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[48]  AJ McMichael,et al.  Have increases in solar ultraviolet exposure contributed to the rise in incidence of non-Hodgkin's lymphoma? , 1996, British Journal of Cancer.